The global personalized medicine market size was valued at USD 514.33 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.95% from 2022 to 2030. The growth of the market is attributed to factors such as the growing demand for novel drug discovery to combat the growing incidence of cancers and other diseases across the globe. Moreover, numerous collaborations among researchers and market players are anticipated to have a positive impact on market growth. For instance, in February 2022, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) in Germany collaborated for strategic, structural, and content-specific efforts to implement precision medicine in healthcare.
The COVID-19 pandemic outbreak hindered the continuance of research for novel drug discovery. However, technology-oriented outcomes in the market such as telemedicine came into persistence after the incidence of pandemic situation. Many clinical consultations are facilitated online to increase subject convenience and avoid the spread of contagious infections. Moreover, the COVID-19 pandemic has propelled the demand for personalized medicine in gauging an individual’s immunity to combat COVID-19 infection. For instance, a research study published in Elsevier in 2020 has indicated that COVID-19 infections are linked with gene variants on chromosomes and loss of variants present on the X-chromosome.
The increasing prevalence of rare diseases is also anticipated to boost the growth of the market. The increasing level of understanding and correlation of characteristics of the human genome has paved the way for efforts on devising various personalized medicine and therapeutic exercises. For instance, in September 2022, a research study carried out at the University of California at Irvine proposed a novel technique for the management of inherited retinal diseases (IRDs) by using precision genome editing that is very specific to an individual’s requirements.
Personalized medicine is also increasingly used for applications in companion diagnostics that are precisely designed for the determination of the viability of subjects to a specific treatment and to gauge the subject’s response to a therapeutic regime. Companion diagnostics play an essential role in devising efficient precision medicine considering the micro environment, patient’s genome characteristics, ethnicity, and lifestyle choices. There are an increasing number of FDA approvals for companion diagnostics due to the rising demand. For instance, in October 2020, Roche achieved U.S. FDA approval for the expansion of the Cobas EGFR Mutation Test to be used for the treatment of non-small cell lung cancer.
The market players are extensively working towards collaborations and acquisitions along with huge capital investments to devise the best-personalized medicine strategy that could possibly cure a disease. For instance, in July 2022, Certara declared a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) for the development of a novel biosimulation software for leveraged CAR T-cell therapy dosing for subjects with multiple myeloma.
Personalized nutrition and wellness held the largest share of over 55.0% in 2021. The growth in the segment is due to the extensive consumption rate and market penetration. Further, the high rate of over-the-counter (OTC) sales of nutrition products boosts the demand due to lowered regulatory implications. For instance, in March 2022, the American Heart Association features that nutrition scientists are working towards precision nutrition to combat cardiovascular diseases based on the unique responses for specific foods and nutrients.
The personalized medicine therapeutics segment is expected to witness the highest growth over the forecast period. The rise in demand for genomics based therapeutics and biopharmaceuticals based on specifically sequenced data is primarily contributing to the growth of the segment. Moreover, the emergence of high-end sequencing to effectively reduce the cost of genome sequencing nurtures the growth of the market.
North America accounted for the largest share of over 45.0% in 2021. This is attributed to the support from research institutes and pharmaceutical giants. Personalized medicine is now preferred for all kinds of diseases and therefore is part of research on any given disease and drug discovery. There are emerging advancements in personalized medicine for diagnostics in the region. For instance, in January 2021, Illumina, Inc. develops the TruSight Oncology 500 (TSO 500) assay that uses nucleic acids from tumor cells and capably identifies as many as 523 cancer biomarkers.
Asia Pacific is estimated to be the fastest-growing segment over the forecast period due to increased demand for personalized medicine in diagnostics and the growing demand for novel therapeutic drugs to fight increased incidence of diseases in the region.
Key players operating in the market are focused on strategic collaborations, new product launches, and geographical expansions in emerging and favorable regions across the globe. For instance, in January 2022, Panaceutics Nutrition and Viocare declared a collaborative agreement to produce personalized nutrition for healthcare providers and their subjects using a high-end technology interface by integrating Viocare’s nutrition assessment software with personalized nutrition supplementation for making an end-to-end service platform. Some prominent players in the global personalized medicine market include:
GE Healthcare
Illumina, Inc.
ASURAGEN, INC.
Abbott
Dako A/S
Exact Sciences Corporation
Danaher Corporation (Cepheid, Inc.)
Decode Genetics, Inc.
QIAGEN
Exagen Inc.
Precision Biologics
Celera Diagnostics LLC
Biogen
Genelex
International Business Machines Corporation (IBM)
Genentech, Inc.
23andMe, Inc.
Report Attribute |
Details |
Market size value in 2022 |
USD 538.93 billion |
Revenue forecast in 2030 |
USD 922.72 billion |
Growth rate |
CAGR of 6.95% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
GE Healthcare; Illumina, Inc.; ASURAGEN, INC.; Abbott; Dako A/S; Exact Sciences Corporation; Danaher Corporation (Cepheid, Inc.); Decode Genetics, Inc.; QIAGEN; Exagen Inc.; Precision Biologics; Celera Diagnostics LLC; Biogen; Genelex; IBM; Genentech, Inc.; 23andMe, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global personalized medicine market report on the basis of product and region:
Product Outlook (Revenue, USD Billion, 2018 - 2030)
Personalized Medicine Diagnostics
Genetic Testing
Direct-To-Consumer (DTC) Diagnostics
Esoteric Lab Services
Esoteric Lab Tests
Personalized Medicine Therapeutics
Pharmaceutical
Genomic Medicine
Medical Devices
Personalized Medical Care
Telemedicine
Health Information Technology
Personalized Nutrition & Wellness
Retail Nutrition
Complementary & Alternative Medicine
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Italy
Asia Pacific
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global personalized medicine market size was estimated at USD 514.33 billion in 2021 and is expected to reach USD 538.93 billion in 2022.
b. The global personalized medicine market is expected to grow at a compound annual growth rate of 6.95% from 2022 to 2030 to reach USD 922.72 billion by 2030.
b. North America dominated the personalized medicine market with a share of 48.42% in 2021. This is attributable to the increasing adoption of NGS methods and healthcare IT systems in clinical workflow along with supportive government policies and funding.
b. Some key players operating in the personalized medicine market include GE Healthcare; Illumina, Inc.; Asuragen, Inc.; Abbott Laboratories; Dako A/S; Exact Science Corporation; Danaher Corporation (Cepheid, Inc.); Decode Genetics, Inc.; Genelex Corporation; Exagen Diagnostics, Inc.; Precision Biologics, Inc.; QIAGEN; Celera Diagnostics LLC; and Biogen, Inc.
b. Key factors that are driving the personalized medicine market growth include the advancement of next-generation sequencing, a growing number of companion/associated diagnostics, an increasing number of retail clinics across the developed regions of North America and Europe, an increasing prevalence of cancer, and increasing usage of biomarkers for PM cancer therapy.
b. The personalized nutrition and wellness product segment dominated the personalized medicine market and accounted for the largest revenue share of 58.89% in 2020.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.